Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically equivalent to Evoclin® Foam, 1%, a product of Mylan (NASDAQ:VTRS) Pharmaceuticals Inc.
The market for Evoclin® Foam, 1% generated annual sales of approximately $5.8 million, according to IQVIA™ sales data for the 12-month period ending December 2024.
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a globally recognized pharmaceutical company that conducts research and has a presence in Branded, Generics, and OTC segments. The company focuses on therapeutic areas of respiratory, dermatology, and oncology.
Glenmark operates in over 80 countries and maintains 11 world-class manufacturing facilities located across four continents. The company was ranked among the Top 100 biopharmaceutical companies by Pharmaceutical (TADAWUL:2070) Sales in 2023, according to Scrip 100. In 2024, Generics Bulletin placed it in the Top 50 Generics and biosimilar companies ranked by sales.
In 2023, Glenmark’s targets for reducing Green House Gas (GHG) emissions were approved by the Science Based Target (NYSE:TGT) initiative (SBTi), making it the second pharmaceutical company in India to achieve this recognition. Over the past decade, Glenmark’s CSR interventions have positively impacted over 3.3 million lives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.